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Abstract
The association between diabetes mellitus (and its micro- and macro-vascular complications) and erectile dysfunction is widely
known and the presence of hypogonadism may further complicate sexual dysfunction and quality of life, given the association
between hypogonadism and reduced libido, ejaculatory disorders, and depressive symptoms. However, the recent introduction of
novel antidiabetic agents with a wide range of mechanism of action may have a significant impact both on male and female
sexuality directly (by inducing side effects as urinary tract infections) and indirectly (improving metabolic status and reducing
diabetes complications behind sexual dysfunctions). To date only few papers are reporting the sexual effects of these treatments
and, often, these are not comparable in their results. Conversely, female sexual dysfunctions are somehow under-investigated.
Data on prevalence is heterogeneous and specific pathogenic mechanisms, as well as the burden of psychological factors, are still
heatedly debated. The aim of this narrative review is to summarize current knowledge and stressing out the need to diagnosemale
and female sexual dysfunctions also in light of the impact of treatments with novel antidiabetic agents. This would highlight the
still unmet needs for sexual care in a diabetes care setting and could represent an incentive for future discussions, as well as a
required theoretical starting point for studies on this subject.
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1 Introduction
Diabetes mellitus (DM) represents one of the leading causes
of mortality worldwide, with an estimated related death of at
least 1.3 million in 2013 [1]. prevalence of 382 million people
with DM worldwide has been reported in the same year.
Current projections suggest that this number will reach 592
million by the year 2035 [2, 3]. The association between DM
and erectile dysfunction and a decrease in libido, or loss of a
sex drive both in male and female is widely known and the
presence of hypogonadism may further complicate sexual
dysfunction and quality of life, given the association between
hypogonadism and reduced libido, ejaculatory disorders, and
depressive symptoms.
Type 2 DM (T2DM) represents the most common form of
DM, showing the highest prevalence increase, due to its
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association with obesity [4–6]. Intensive glucose control pro-
vided a significant reduction in the incidence of cardiovascu-
lar (CV) events and mortality or total mortality in patients with
advanced T2DM, thus suggesting that glucose lowering is not
enough [7–10].
Several new classes of drugs for T2DM treatment have
recently been introduced in the clinical practice. Among them,
the sodium-glucose type 2 co-transporter inhibitors (SGLT2i)
represents the last category of oral antihyperglycemic agents.
Their anti-diabetic effect is based on the inhibition of glucose
reabsorption in the proximal renal tubule thus determining an
increase in urinary excretion of glucose and a reduction of its
circulating levels [11]. Both the American Diabetes
Association (ADA) and the European Association for the
Study of Diabetes (EASD) recommended the use of SGLT2i
as second-line drugs after failure of fist-line regimes or in
metformin intolerant patients [12]. These drugs seem very
promising as phase III studies have shown a high degree of
tolerance and a higher efficacy on glucose control compared
sulfonylurea or dipeptidyl peptidase IV inhibitors (DPP4i)
[13]. However, the most interesting data concerns the effects
of cardiovascular (CV) protection. Accordingly, well-
designed controlled trials on wide sample cohorts demonstrat-
ed the efficacy of empagliflozin, canagliflozin and
dapagliflozin in reducing the incidence of major CV events
(MACE), total and CV mortality and the incidence of hospi-
talizations for heart failure (HF) [14–16]. Conversely, DPP4i
have been shown a neutral effect on CV outcomes, whereas
CV protection has been also documented with the use of
glucagon-like peptide-1 receptor agonists (GLP-1RA) [17].
Sexual dysfunctions represent a wide spectrum of disorders
such as erectile dysfunction (ED), premature or delayed ejac-
ulation, anejaculation or retro-ejaculation in men, genital
arousal disorder in women and hypoactive sexual desire or
anorgasmia in both (Table 1). Despite their prevalence is not
negligible in the diabetic population, sexual disorders remain
often underdiagnosed and undertreated [18, 19]. The presence
of hypogonadism, which diabetic patients are exposed to, may
further complicate sexual dysfunctions and quality of life in
men, due to its association with reduced libido, ejaculatory
disorders, and depressive symptoms [20]. In addition, much
evidence suggests that ED can represent an early marker of
forthcoming CV diseases (CVD), particularly in the diabetic
population [21] and, thus, the research of ED in DM patients
would be relevant for CVD prevention. Importantly, limited
attention has been paid by available guidelines on diagnosis
andmanagement of sexual disorders in diabetic patients so far.
Also, the recent introduction of novel antihyperglycemic
agents, with a wide range of mechanisms of action, may result
in a significant impact on both male and female sexuality
either directly, by inducing side effects such as urinary tract
infections, or indirectly, by improving metabolic status and
reducing diabetes complications and CV risk, behind sexual
dysfunctions.
The specific impact of these novel antihyperglycemic
agents on sexuality has been poorly investigated. Therefore,
the aim of this narrative review is to summarize the available
evidence linking DM and sexual dysfunction, particularly fo-
cusing on the impact of new antihyperglycemic treatments.
2 Impact of DM on male sexual function
2.1 Erectile dysfunction
The prevalence of ED among subjects with DM is quite var-
iable and is tightly related to DM duration, degree of obesity,
and micro- and macro-vascular complications [22, 23].
Another factor t ight ly associated with T2DM is
hypogonadism [20]. In patients with T2DM, low testosterone
(T) may further complicate sexual dysfunction and quality of
life, due to its association with reduced libido, ejaculatory
disorders, and depressive symptoms [see below; 20,23].
Similarly, genito-urinary infection, quite common in the dia-
betic population, can further complicate the clinical setting
[23; see below]. Fedele et al. [22] carried out the largest study
on this topic, including 9869male diabetic patients (age range,
20–69 years), randomly selected from 178 diabetes centers in
Italy. The prevalence of ED among those with type 1 DM
(T1DM) was 26% versus 37% among those with T2DM;
however, the difference was reduced when age was consid-
ered in a multivariate model [22].More recently, Corona et al.,
[23] investigated the prevalence of ED in a large series of men
with recently (< 2 years) diagnosed with DM. Among 499
subjects enrolled from 27 Italian diabetes centers, the authors
reported mild ED in 19.4%, mild-to-moderate in 15.4%, mod-
erate in 10.4%, and severe in 21.6% of patients [23]. Finally, a
meta-analysis including 145 studies and 88,577 men (mean
age: 55.8 ± 7.9 years), showed an overall ED prevalence of
52.5% (95% CI, 48.8 to 56.2), after adjusting for publication
bias, being 37.5% in T1DM and 66.3% in T2DM [19]. In
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associated with 3.5-fold increased risk of ED when compared
to healthy controls. In addition, as expected, the authors re-
ported that the concomitant prevalence of hypertension in-
creased the risk.
Fewer studies have investigated the incidence of ED in
DM. Fedele et al., [24] prospectively evaluated a subgroup
of 1010 subjects without ED on enrolment up to 2.8 years
on average, showing an incidence of ED of 68 cases/1000
subjects per year. Similar results were published around the
same time by the Massachusetts Male Aging Study (51 cases/
1000 subjects per year) [25]. De Berardis et al. [26], in another
Italian study enrolling 670 men with T2DM followed every
6 months for up to 3 years, reported a higher incidence (166.3
per 1000 person-years). Conversely, a lower incidence (25/
1000 person-years) was reported by Klein et al. [27] in a 10-
year cumulative US study in 264 T1DM men who were less
than 30 years of age at diagnosis of diabetes.
Despite this evidence, the presence of ED in diabetic men is
still poorly evaluated in routine clinical practice. Accordingly,
a Danish study reported that only 33% of men with T2DM
reported that their general practitioner had brought up sexual-
ity in the consultation [28]. Similar results were more recently
reported by Bjerggaard et al. [29], who showed that about
50% of sexually inactive men with T2DM declared that their
sexual life did not meet their sexual needs. Since ED repre-
sents an early marker of forthcoming CVD particularly in the
diabetic population [21], recognizing this symptommight mo-
tivate diabetic men to improve their metabolic control and
treatment adherence.
2.2 Hypogonadism
Male hypogonadism is estimated to affect between 20% and
64% of men with T2DM, depending on the population char-
acteristics [30, 31]. Longitudinal data have clearly demon-
strated a bidirectional relationship linking hypogonadism
and T2DM. Meta-analysis of the available data showed that
subjects who developed T2DM at follow up had lower total T
level at baseline (−1.65[−3.01; −0.29] nmol/L), when com-
pared to controls [32]. In addition, the analysis of data from
1306 men included in the database of the Health Management
Center in Taiwan, showed that DM and prediabetes condition
significantly increased the risk of hypogonadism (total T <
10.4 nM) at follow up [33].
The specific mechanisms underlining the association be-
tween insulin insensitivity, T2DM and androgen deficiency
are not completely understood. Either central or peripheral
mechanisms have been considered [30, 31]. Increased body
fat represents, most probably, the major player, and the first
pathogenic step, in impairing the hypothalamic-pituitary activ-
ity. Longitudinal data from European Male Aging Study, in-
cluding more than 2000 community-dwelling men, with a me-
dian follow up time of 4.3 years, have documented that obesity
at baseline, and weight gain during the follow up, were the best
predictors of the development of secondary hypogonadism
[34]. In addition, lean men, as well as those who lost weight,
were more prone to recover from secondary hypogonadism
[34]. Animal data are in line with these observations. In a rabbit
model of metabolic syndrome (MetS) and hypogonadotropic
hypogonadism - obtained by feeding animals with a high fat
diet for 12 weeks – it was demonstrated that metabolic derange-
ments are able to induce a hypothalamic inflammation, leading
to GnRH secretion impairment, totally restored by physical
activity and weigh loss [35]. Different peripheral mechanisms
have also been advocated. Other animal models have suggested
that hypogonadism can induce insulin resistance in skeletal
muscle, via androgen receptor (AR)-dependent mechanisms,
involving a decreased peroxisone proliferator-activated receptor
γ co-activatorα, which in turn promotes mitochondrial biogen-
esis and skeletal muscle oxidative fibers [36]. In line with these
data, Kelly et al., [37] showed that testicular feminized mice
(Tfm), which are characterized by very low T level and im-
paired AR, displayed significantly reduced GLUT 4 and
glycolitic enzymes in muscle.
Androgens can profoundly affect all steps of male sexual
response cycle [38–40]. Accordingly, in hypogonadal men, T
replacement therapy can improve all aspects of male sexual
function, although its role in more complicated form of
arteriogenic ED, such as in DM, is less evident and revised
elsewhere [38–40]. Similarly, several non-controlled observa-
tional data have documented that TRT can improve metabolic
control in T2DM. However, data from randomized controlled
trials (RCTs) are more conflicting and revised elsewhere [41].
2.3 Effects of new anti-diabetic drugs on male
sexuality and hypogonadism
The knowledge of the effects of the new anti-diabetic drugs
including DPP4i, SGLT2i, and GLP1RA on male sexual and
gonadal function is so far limited. Indeed, only few studies
reported the effect of these therapies on T levels and sexual
function. In addition, the available data were collected in dif-
ferent subset of diabetic patients and thus not comparable in
their results.
Indirect evidence, mainly derived from studies performed
in animal models, suggests that DPP4i might improve erectile
function in T2DM patients, based on their potential effect to
promote vascular repair and endothelial function. In a mouse
model of hind limb ischemia, DPP4i markedly increased the
release and mobilization of circulating endothelial progenitor
cells from bone marrow, through an eNOS-related pathway
[42]. In addition, DPP4i might indirectly improve endothelial
function, through pituitary adenylate cyclase-activating poly-
peptide (PACAP), a peptide isolated from the hypothalamus,
which may enhance gonadotropin release, and, subsequently,
sex steroids level, and may exert vasorelaxant effects
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mediated by VEGF [43]. Finally, DPP4i have been shown to
slow down atherogenesis [44].
Limited positive outcomes are also available for SGLT2i.
In animal model of T2DM-associated erectile dysfunction, an
experimental study demonstrated that short-term chronic treat-
ment with empagliflozin, significantly improved erectile per-
formance in response to electrical stimulation of the cavernous
nerve, by increasing the nitrergic relaxation of erectile tissue
[45]. Few experimental and clinical studies provided encour-
aging results on the potential effectiveness of GLP1RA in
improving sexual symptoms in T2DM patients, probably me-
diated by the positive effects on gonadal function, visceral
adiposity, and T levels. One study in an aging mouse model
demonstrated that treatment with exenatide increased testis
weight and volume, as well as T levels [46]. Similarly, a recent
12-week interventional study in obese T2DM patients dem-
onstrated that short-term combined treatment with exenatide
and metformin significantly increased total T levels and sex-
ual function, being more effective than glimepiride-metformin
combination [47]. As expected a more pronounced effect was
reached in patients who had a greater weight loss, and corre-
lation analysis clearly showed that changes in waist circum-
ference alone explained about 20% of the variance in T levels,
therefore indicating mediation by the metabolic effects [47].
In line with these data, liraglutide was shown to improve ei-
ther levels or sexual function in patients with obesity-
associated hypogonadism, poor responders to lifestyle modi-
fications [48], and to potentiate the effects of TRTand metfor-
min on erectile dysfunction, in T2DM obese patients with
hypogonadism [49]. (See Table 2 and Fig. 1).
3 Impact of DM on female sexual function
3.1 Female sexual dysfunctions
Sexual dysfunction (SD) is an under-investigated complication
of diabetes not only in male but also in female patients. The
prevalence of Female Sexual Dysfunctions (FSD) in T1DM
ranges from 18% to 71%, whereas in T2DM there is a more
heterogeneous prevalence, ranging from 12% to 88% [18]. The
pathophysiological correlates of FSD in metabolic disorders,
like diabetes, are far from being elucidated. Nevertheless, as
opposed to the male counterpart [50, 51], in diabetic female
population, SD seems to be more strongly related to psycho-
logical factors and depressed mood than to metabolic alter-
ations per se. In particular, hyperglycemia and neurovascular
alterations, as well as psychological disorders or recurrent gen-
ital infections, common in female diabetic patients, could have
detrimental effects on sexual function [52].
All the domains of sexual cycle in women including desire,
arousal, lubrication, orgasm and satisfaction were reported to be
affected in both T1DM and T2DM patients. However, a recent
systemic review suggests a greater impact of DM on desire than
on the other sexual domains [53]. Genital arousal and lubrica-
tion are neuro-vascular events that represent an interplay be-
tween smooth muscle relaxation and contraction, similar to
what happens for male. Accordingly, similar to what observed
for ED, genital arousal disorder in diabetic women might be
related to neurovascular alterations due to chronic hyperglyce-
mia and vascular impairment in genital districts with altered
genital response to sexual stimuli [54]. Based on the concept
that sexual satisfaction in women is more dependent on psy-
chological and relationship factors than to biological ones, a
previous study failed to demonstrate that reduced sexual satis-
faction at baseline could predict the onset of major cardiovas-
cular events in women [55]. As reported for men, also hormonal
milieu can affect sexuality in women with DM. Available data
are mainly derived from animal models. Insulin and insulin-like
growth factors (IGFs) can regulate the activities of aromatase
and 3β-hydroxysteroid dehydrogenase, which are involved in
steroid synthesis [56]. Some experimental data also suggest that
insulin can contribute in maintaining estrogen receptor expres-
sion at the hypothalamus level, having a role in lordosis and
solicitation behavior in female rats [57]. In addition, peripher-
ally, both insulin and other growth factors stimulate the prolif-
eration of mouse vaginal epithelial cells in culture and, in the
vagina, estrogens seem to stimulate the production of IGF and
IGF binding proteins [58, 59].
Sexual pain, is another important issue related to women
sexuality. Unexplained vulvodynia has been proposed as an
unrecognized sign of diabetic neuropathic syndrome [60]. In a
recent consensus [61], however, DM was not considered
among the potential pathogenic mechanisms causing/
worsening unexplained vulvodynia, suggesting that more
studies are needed to better clarify this point.
3.2 Effects of new anti-diabetic drugs on female
sexuality
Previous evidence demonstrated that weigh loss plays an im-
portant influence on the improvement of sexual function in
T2DM women [62]. In fact, body image and body weight
concerns have a negative impact in sexual functioning of
DM patients [63]. Hence, physicians should consider the im-
pact of losing weight in the choice of the most appropriate
glucose-lowering therapies in female patients complying of
sexual dysfunction.
As reported above, several drugs are available for T2DM
treatment and some of them have a good impact on body
weight like GLP-1RA and the most recent SGLT2i. Similar
to what reported in men, it could be expected that the use of
these drugs will have a positive effect on losing weight,
resulting in better sexual outcomes. However, no studies have
evaluated this point so far.
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4 DM genitourinary tract infections
Another complication in DM is the possibility to contract
common infections, compared with patients without diabetes
[64]. Urinary tract infections (UTI) and mucosal candidiasis
are quite common and frequently more severe in people with
diabetes than in the general population. Several studies have
documented an association between the degree of glycemic
control and the incidence or severity of infectious complica-
tions but the relationship between DM, hyperglycemia, im-
mune function and infections is complex and many issues
remain unresolved [65]. In this section, a summary of the
impact of the most common UTI observed in DM population
and their relationship with male and female sexual function
will be analyzed. In addition, the possible contribution of
SGLT2i on UTI will be also addressed.
4.1 Epidemiological data
The prevalence of asymptomatic bacteriuria (ASB) has been
reported to range between 8 and 26% in patients with DM
[66], without a clear association with metabolic control.
Furthermore, meta-analytic data estimated the risk for ASB
to be three times more common in diabetic patients compared
Table 2 Characteristics of the studies evaluating the effect of new anti-diabetic drugs on male sexuality and hypogonadism
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DPP4i Inhibitors of dipeptidyl peptidase 4; SGLT2i Sodium-glucose co-transporter-2 inhibitors; GLP1RA Glucagon-like peptide-1 receptor agonists
Fig. 1 Summary of the effects of
novel anti-hyperglicemic drugs.
DPP4-Inhibitors of dipeptidyl
peptidase 4; SGLT2i- Sodium-
glucose co-transporter-2 inhibi-
tors; GLP1RA-Glucagon-Like
Peptide 1 Receptor Agonists
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to the controls (12.2% vs. 4.5%) [66]. The same study showed
a higher risk in men compare to women [66].
UTI are one the most common infections in diabetes pa-
tients, with a reported incidence of 12.2 per 100 person-years
for diabetic women, compared to 6.7 for non-diabetic women
(RR 1.8; 95%CI 1.2–2.7) [67]. The risk was tightly related to
diabetes duration and was lower in men compared to women
[67].
Patients with poorly controlled DM, are more prone to
develop genital mycotic infections. Candida albicans is the
most common pathogen causing balanitis and it is also the
dominant cause of vulvovaginal candidiasis in women with
diabetes [68].
Male Accessory Gland Inflammations/Infections (MAGI)
represents another group of conditions frequently associated
with DM. Condorelli et al. [69] reported an increased frequen-
cy of MAGI (about 43%) among patients with T2DM, sug-
gesting that MAGI may represent a possible undiagnosed
complication of the diabetic population. In addition, La
Vignera et al., [70] further reported peculiar ultrasound char-
acteristics (lack of reduction of interparietal thickness after
ejaculation and alteration of the relationship between glandu-
lar fund and body) of the seminal vesicles in DM patients,
particularly among those with diabetic autonomic neuropathy,
suggestive of functional atony [71].
4.2 Impact on male and female sexual function
Whereas acute and symptomatic UTI, as well as recurrent
genital mycotic infections, have an obvious detrimental neg-
ative effect on male and female sexual function, the role of
ASB and chronic abacterial MAGI is more conflicting.
However, it has been suggested that recurrent infections can
contribute to the development of low urinary tract symptoms
(LUTS), in turn showing an independent association with ED
[72, 73]. Similarly, an increasing body of evidence supports an
association between Lower Urinary Tract Dysfunction
(LUTD) and FSD [74]. In particular, the presence of urinary
incontinence (UI) (tightly associated with DM) and UTI dou-
bles the risk for reduced libido compared to non-incontinent
women, and increasing vaginal dryness and dyspareunia [74].
In greater detail, women with detrusor overactivity and asso-
ciated UI had the greatest degree of sexual dysfunction. While
pure urgency UI is a risk factor for decreased lubrication and
increased coital pain, mixed UI was associated with less sex-
ual satisfaction [75].
4.3 Impact of SGLT2i on male and female
genitourinary tract infections
Clinical trials have shown that SGLT2i are generally well
tolerated. However, due to their mechanism of action, they
are associated with an increased risk for genital mycotic
infections, or serious adverse events, such as serious UTI.
The increased risk of genital mycotic infections is likely to
be related to the presence of urinary glucose, although no
definitive dose relationship between incidence of infection
and SGLT2 inhibitor treatment has been established to date.
Genital mycotic infections associated with SGLT2i occurred
more commonly in females and patients with a history of such
infections [76–78]. Post-marketing reports have led to a warn-
ing from the Food and Drug Administration (FDA) about the
possibility of severe urinary tract infection and pyelonephritis
in patients treated with SGLT2i [79]. Health care professionals
have been advised to evaluate patients for signs and symptoms
of UTIs and GI and treat such infections promptly, if
indicated.
5 Conclusions
Sexual dysfunctions are frequently observed inmen andwom-
en with DM. ED should be routinely investigated in all men,
since it is an early marker of forthcoming CVD. In addition,
either in men or women sexual dysfunction can severely im-
pair quality of life, resulting in worse metabolic control and
poor therapeutic compliance. An early identification of the
problems, and an adequate discussion, can lead to a virtuous
cycle, allowing lifestyle modifications and better
glycometabolic control. While the use of one of the most
widely prescribed drugs to treat T2DM, metformin, is known
to have a beneficial effect on male and female reproductive
function, other drugs commonly used in more complicated
forms, such as insulin and sulfonylureas, may have a negative
effect on weight and thus on gonadal and sexual function. The
novel classes of antihyperglycemic drugs, have shown prom-
ising metabolic effects: the positive (GLP1RA and SGLT2i)
or neutral (DPP4i) effect on weight could be an interesting,
though indirect, way to improve the gonadal and sexual func-
tion in diabetic subjects complaining of sexual dysfunction.
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